NCT05160480Recruiting
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 9 (estimated)
- First submitted
- 2 Dec 2021
- Start date
- 7 Jun 2024
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- University of California, Davis
- Diseases
- Prostate cancer, Neuroendocrine tumours
- NCT number
- NCT05160480
What you commit to
- Study type: Observational
- Planned participants: 9
- From 7 Jun 2024 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety
Other
- Recent administration of long-acting somatostatin analogs
- Adults unable to consent
- Pregnant/lactating persons
- Prisoners
- Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner
- Uncontrolled claustrophobia
Who the study is looking for
- Persons \>18 yo with suspected prostate cancer metastasis
- Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.
- 68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)
- Persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
- Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.
Criteria the registry did not label
- 18F-PSMA (n=3) and 68Ga-PSMA (n=3)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UC Davis EXPLORER Molecular Imaging Center Coordinator of this site? Confirm its status | Sacramento | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.